The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Open accessAbstract
BACKGROUND: Uveal melanoma is a disease that is distinct from cutaneous melanoma, with a low tumor mutational burden and a 1-year overall survival of approximately 50% in patients with metastatic uveal melanoma. Data showing a proven overall survival benefit with a systemic treatment are lacking. Tebentafusp is a bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target glycoprotein 100-positive cells. METHODS: In this open-label, phase 3 trial, we randomly assigned previously untreated HLA-A*02:01-positive patients with metastatic uveal melanoma in a 2:1 ratio to receive tebentafusp (tebentafusp group) or the investigator's choice of therapy with single-agent pembrolizumab, ipilimumab, or dacarbazine (control group), stratified according to the lactate dehydrogenase level. The primary end point was overall survival. RESULTS: A total of 378 patients were randomly assigned to either the tebentafusp group (252 patients) or the control group (126 patients). Overall survival at 1 year was 73% in the tebentafusp group and 59% in the control group (hazard ratio for death, 0.51; 95% confidence interval [CI], 0.37 to 0.71; P<0.001) in the intention-to-treat population. Progression-free survival was also significantly higher in the tebentafusp group than in the control group (31% vs. 19% at 6 months; hazard ratio for disease progression or death, 0.73; 95% CI, 0.58 to 0.94; P = 0.01). The most common treatment-related adverse events in the tebentafusp group were cytokine-mediated events (due to T-cell activation) and skin-related events (due to glycoprotein 100-positive melanocytes), including rash (83%), pyrexia (76%), and pruritus (69%). These adverse events decreased in incidence and severity after the first three or four doses and infrequently led to discontinuation of the trial treatment (2%). No treatment-related deaths were reported. CONCLUSIONS: Treatment with tebentafusp resulted in longer overall survival than the control therapy among previously untreated patients with metastatic uveal melanoma. (Funded by Immunocore; ClinicalTrials.gov number, NCT03070392; EudraCT number, 2015-003153-18.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, tebentafusp-tebn, a bispecific fusion protein consisting of a soluble TCR specific to gp100 (expressed by melanoma cells) linked to an anti-CD3 single-chain antibody fragment that targets T cells, has been approved for the treatment of metastatic uveal melanoma based on an OS benefit observed in a phase III trial199.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [199]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Self-citationDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Checking the Cox model with cumulative sums of martingale-based residuals
LIN, D. Y., WEI, L. J., & YING, Z. (1993) · Biometrika · doi:10.1093/biomet/80.3.557 · Cited by 1,432
Very Long-Term Prognosis of Patients with Malignant Uveal Melanoma
Kujala, E., Mäkitie, T., & Kivelä, T. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.03-0538 · Cited by 1,046
Jager, M. J., Shields, C. L., Cebulla, C. M., Abdel‐Rahman, M. H., Grossniklaus, H. E., Stern, M., Carvajal, R. D., Belfort, R. N., Jia, R., Shields, J. A., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0158-0 · Cited by 857
Self-citation
Cited by
Sorted by citations
Items 701–800 of 935
Impact of Precision Medicine in Oncology
Buchbinder, E. I., & Hodi, F. S. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000641 · Cited by 1
Mélanome métastatique, immunothérapie et survie à long terme : où en sommes-nous ?
Robert, C. (2023) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2023.03.020 · Cited by 1
Kogoniya, L. M., & Васильевна, М. Е. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-444 · Cited by 1
A centrosome-related gene signature for predicting the overall survival of uveal melanoma
Yu, X., Guo, X., Li, W., & Li, J. (2024) · Translational Cancer Research · doi:10.21037/tcr-23-1486 · Cited by 1
Effects of Source and Shadow Shield Geometry on the Scattering of Gamma Rays
PLESSET, M. S., Hastings, C., & Cohen, S. T. (1948) · Cited by 1
Multifactorial remodeling of the cancer immunopeptidome by interferon gammaPreprint
Newey, A., Yu, L., Barber, L. J., Choudhary, J. S., Bassani‐Sternberg, M., & Gerlinger, M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.23.485466 · Cited by 1
The greatest achievements in oncology in 2022 – melanoma and skin carcinomas
Rutkowski, P. L. (2022) · Archives of Medical Science · doi:10.5114/aoms/155247 · Cited by 1
Self-citationPersonalized ocular oncology care: how far have we come?
Jager, M. J. (2024) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2024.05.010 · Cited by 1
Bechrakis, N. E. (2024) · Springer Reference Medizin · doi:10.1007/978-3-662-65929-8_166-1 · Cited by 1
Systemic Treatment Kimmtrak for Metastatic Uveal Melanoma
Heindl, L. M., & Fan, W. (2024) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-2299-3941 · Cited by 1
Wessely, A., Lischer, C., Weich, A., Kammerbauer, C., Güse, E., Koch, E. A. T., Lai, X., Dörrie, J., Erdmann, M. A., Voskens, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.14.679939 · Cited by 1
Obenaus, M., Poupault, C. L., McGinnis, C. S., Prange, C. J., Jiang, H., Su, L., Chen, X. T., Miao, Z., Muldoon, J. J., Yao, W., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.04.692214 · Cited by 1
Der Herbst ist da und die dritte Impfung kommt
Weninger, W. (2021) · hautnah · doi:10.1007/s12326-021-00484-0
Treatment of Locally Advanced Cervical Cancer With Kidney Failure and Comorbidities
Bravo, E. (2021) · ONCOLOGY · doi:10.46883/onc.2021.3511.0741
Quoi de neuf en dermato-oncologie ?
Aubin, F. (2021) · Annales de Dermatologie et de Vénéréologie - FMC · doi:10.1016/s2667-0623(21)01529-4
Meyer, M., Chrysou, K., Stamatiou, A., Gilabert, M., Gómez, R. G. H., Latifyan, S., Masmoudi, S., Mederos, N., Perrinjaquet, C., Berthold, D., et al. (2022) · JMIG · doi:10.53738/revmed.2022.18.767.182
Un traitement pour le mélanome uvéal
Manus, J.-M. (2022) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(22)00153-8
Novel Therapies in Clinical Development for Advanced Disease
Arraez, Á. S., Maciá, S., & Castañón, E. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.107089
Carr, M. J., Ko, J., Swetter, S. M., Woodman, S. E., Sondak, V. K., Margolin, K. A., & Zager, J. S. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm110.pub2
Leach, E., Collins, L. C., Watson, A. G., Abdullah, S. E., Stanhope, S., & Ranade, K. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-sitc2022.0620
Self-citationEntstehung und Entwicklung des Hauttumorzentrums Karlsruhe
Raguz, J. M., Klemke, C., & Jäger, M. (2022) · Aktuelle Dermatologie · doi:10.1055/a-1959-2873
(2022) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-022-00861-2
Pettinger, C., Livings, C., Grochot, R. M., Furness, A. J. S., & Lopez, J. S. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006073
Creating a Science Project: Advice from Personal Experience
Jager, M. J. (2022) · Springer eBooks · doi:10.1007/978-3-031-08250-4_39
Metastatic Behavior of Uveal Melanoma: From Biology to Treatment
Koç, İ., & Kıratlı, H. (2022) · Springer eBooks · doi:10.1007/978-3-031-08250-4_15
Melanoma treatment: what’s next?
Emri, G., Ványai, B., Soltész, L., Szabó, I. L., Várvölgyi, T., Janka, E. A., & Oláh, J. (2022) · Bőrgyógyászati és Venerológiai Szemle · doi:10.7188/bvsz.2022.98.5.3
O’Day, R., McKelvie, P. A., Cherepanoff, S., & McKay, D. (2023) · International Ophthalmology · doi:10.1007/s10792-023-02647-9
A novel brick for bispecific antibody construction
He, Y., Ma, H., Wang, C., Ai, Z., Wu, Q. Y., Chen, H., & Lu, D. (2023) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26492
Zhang, W., Auguste, A., Liao, X., Walterskirchen, C., Bauer, K., Lin, Y.-H., Yang, L., Sayedian, F. H., Fabits, M., Bergmann, M. M., et al. (2023) · doi:10.1158/1078-0432.c.6532800
Zhang, W., Auguste, A., Liao, X., Walterskirchen, C., Bauer, K. H., Lin, Y.-H., Yang, L., Sayedian, F. H., Fabits, M., Bergmann, M. M., et al. (2023) · doi:10.1158/1078-0432.c.6532800.v1
Data from Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma
Wong, D., Luo, P., Znassi, N., Arteaga, D. P., Gray, D., Danesh, A., Han, M., Stutheit-Zhao, E. Y., Pedersen, S., Prokopec, S. D., et al. (2023) · doi:10.1158/2767-9764.c.6551108
Self-citationNeoadjuvant Immunotherapy for Colorectal Cancer: Too Good to Be True?
Venook, A. P. (2023) · JCO Oncology Practice · doi:10.1200/op.23.00119
Göz Hastalıklarında Güncel Çalışmalar IV
Atmaca, F., Karalezlı, A., Yaman, F., Kaderli, S. T., Pehlivanoğlu, S., Tekcan, H., Balcıoğlu, E., Özçelik, F., Alpoğan, O., Keser, S., et al. (2023) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.2538
Champiat, S., Salaün, H., Lucibello, F., Scoazec, J., Besse, B., Lalanne, A. I., Rouleau, É., Metzger, N., Saint‐Ghislain, M., Ryckewaert, T., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00363
Revisiting novel interventions in melanoma
Chaudhry, S. (2023) · IP International Journal of Comprehensive and Advanced Pharmacology · doi:10.18231/j.ijcaap.2023.017
Carlà, M. M., Caputo, C. G., Sammarco, M. G., Giannuzzi, F., Fantozzi, C., Savino, G., Blasi, M. A., & Pagliara, M. M. (2023) · Current Problems in Cancer Case Reports · doi:10.1016/j.cpccr.2023.100253
Bubenzer, R. H. (2023) · Onkologische Welt · doi:10.1055/a-2077-9060
Metastatic uveal melanoma complete response with nivolumab: A case report
Filiz, M. (2023) · Open Journal of Clinical and Medical Images · doi:10.52768/2833-2725/1090
Editorial: Translation of genetically engineered T cells in cancer immunotherapy
Voss, R.-H., Echchannaoui, H., Huang, H., & Xue, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1278677
Hassel, J. C., & Heppt, M. V. (2023) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-023-0066-z
Self-citationRaczka, A., Khakoo, S., Varadarajan, S., Clubley, J., Collins, L. C., Ranade, K., & Benlahrech, A. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-sitc2023.1108
Karlsson, J. W., Sah, V. R., Bagge, R. O., Iqbal, M. M., Alsén, S., Stenqvist, S., Saxena, A., Ny, L., Nilsson, L. M., & Nilsson, J. A. (2023) · eLife · doi:10.7554/elife.91705.1
Uvea-Melanom: Bispezifischer Antikörper mit überragender Überlebenszeit
Gulden, J. (2023) · Deutsches Ärzteblatt · doi:10.3238/persesmo.2023.12.01.08
Comparative phosphoproteome analysis of primary and metastatic uveal melanoma cell linesPreprint
Glinkina, K., González‐Prieto, R., Teunisse, A. F. A. S., Gelmi, M. C., Jager, M. J., Vertegaal, A. C. O., & Jochemsen, A. G. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.06.570407
Identifizierung von Biomarkern und neuen therapeutischen Zielen beim Aderhautmelanom
Wessely, A., Koch, E. A. T., Vera, J., Berking, C., & Heppt, M. V. (2024) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.15225_g
Precision Oncology in Solid Tumors: Key learning points from the 2023 Precision Oncology Summit.
Khan, A. M., Abuali, I. A., Abrams, H. R., Riaño, I., & Funchain, P. (2024) · International Journal of Cancer Care and Delivery · doi:10.53876/001c.94430
3‐Jahres‐Update zur Therapie mit Tebentafusp beim metastasierten Uveamelanom
Hassel, J. C., & Berking, C. (2024) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.15391_g
Self-citationGünenç, D., Özlük, A. A., Yıldırım, U. M., Ascierto, P. A., & Karaca, B. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1355971
Karlsson, J. W., Sah, V. R., Bagge, R. O., Iqbal, M. M., Alsén, S., Stenqvist, S., Saxena, A., Ny, L., Nilsson, L. M., & Nilsson, J. A. (2023) · eLife · doi:10.7554/elife.91705.1.sa3
Guo, L., Sun, X., Kang, K., Zhao, A., & Wu, Y. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001602
Arzneimittelexantheme unter Immun- und zielgerichteter onkologischer Therapie
Ziemer, M., & Livingstone, E. (2024) · Die Dermatologie · doi:10.1007/s00105-024-05350-7
de Melo, A. C., Lucena, E., de Oliveira, D. C. M., & Viola, J. P. B. (2024) · The Oncologist · doi:10.1093/oncolo/oyae112
Weaponizing the bystander T cell army to fight tuberculosis
Cohen, S. B., & Urdahl, K. B. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2407559121
Double hit — bispecific antibodies in cancer therapy
Bogdanowicz, A., Wojas‐Krawczyk, K., Krzyżanowska, N., & Krawczyk, P. A. (2024) · Oncology in Clinical Practice · doi:10.5603/ocp.98901
Current therapeutic strategies for the treatment of ocular melanoma
Kopecký, J., Kubeček, O., Priester, P., Priester, I., & Hlodáková, A. (2024) · Onkologie · doi:10.36290/xon.2024.036
Häufigster okkulärer Tumor des Erwachsenen: Diagnostik und Therapie des Aderhautmelanoms
Ochsenreither, S., de Bucourt, M., Zeitz, O., & Peuker, C. A. (2024) · Trillium Krebsmedizin · doi:10.47184/tk.2024.03.4
Self-citationAndres, E. L., & Block, M. S. (2024) · Springer eBooks · doi:10.1007/978-3-031-59475-5_8
Karlsson, J., Sah, V. R., Bagge, R. O., et al. (2024) · eLife · doi:10.7554/elife.91705.2.sa2
Karlsson, J. W., Sah, V. R., Bagge, R. O., Kuznetsova, I., Iqbal, M. M., Alsén, S., Stenqvist, S., Saxena, A., Ny, L., Nilsson, L. M., et al. (2024) · eLife · doi:10.7554/elife.91705.2
Karlsson, J. W., Sah, V. R., Bagge, R. O., Kuznetsova, I., Iqbal, M. M., Alsén, S., Stenqvist, S., Saxena, A., Ny, L., Nilsson, L. M., et al. (2024) · eLife · doi:10.7554/elife.91705.2.sa0
Karlsson, J., Sah, V. R., Bagge, R. O., et al. (2024) · eLife · doi:10.7554/elife.91705.2.sa1
Neurological complications of cell therapies in haematological malignancies
Hottinger, A. F., Ghesquières, H., & Touat, M. (2024) · Oxford University Press eBooks · doi:10.1093/med/9780198884903.003.0009
Examination of INPP5A in uveal melanoma uncovers novel calcium transientsPreprint
Onken, M. D., Kaltenbronn, K. M., Makepeace, C. M., Piggott, K., & Blumer, K. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.18.613756
Steinberg, H., Ting, S. C., Zensen, S., Ludwig, J. M., Li, Y., Richly, H., Grüneisen, J., Siveke, J. T., Theysohn, J. M., & Schaarschmidt, B. M. (2024) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.13783
Un premier traitement d’un cancer de l’oeil approuvé aux États-Unis et dans l’Union européenne
Dalmat, Y.-M. (2024) · Option/Bio · doi:10.1016/s0992-5945(24)00215-0
Letsch, A. (2024) · Die Onkologie · doi:10.1007/s00761-024-01592-1
Differential aspects of orphan drugs and their value from a social perspective
Hidalgo, A., Fernández, I., Villaseca, J., Abdalla, F., & Zozaya, N. (2024) · doi:10.37666/i22-2024
Matrix metalloproteinases and uveal melanoma
Mandal, A., Varghese, M. V., & James, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-30098-1.00004-5
Francis, J. H. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.10.030
Jennelle, R. L. S., Berry, J. L., & Kim, J. W. (2024) · Springer eBooks · doi:10.1007/978-3-031-67878-3_17
Impact of Treatment Delays on Survival in Uveal Melanoma: Expanded Cohort and Analytical ApproachesPreprint
Moghadam, A., Gill, V., Sabazade, S., Hagström, A., & Stålhammar, G. (2024) · Research Square · doi:10.21203/rs.3.rs-5347347/v1
A synthetic scaffold to target peptide–MHC complexes
Balivada, P. A., Gaglione, S. A., & Birnbaum, M. E. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02513-8
Sajjad, W. (2025) · Pakistan Journal of Ophthalmology · doi:10.36351/pjo.v41i1.1996
Choroidal melanoma treatment: a shift towards vision preservation
Kazemzadeh, K. (2025) · Medical Hypothesis Discovery & Innovation in Optometry · doi:10.51329/mehdioptometry208
Jager, M. J., Ma, S., Pinos, E. D. L., & Bronkhorst, I. H. G. (2025) · Springer eBooks · doi:10.1007/978-3-031-75907-9_7
Réarrangement de ALK dans le cancer pulmonaire non à petites cellules
Naulleau, G., Birsen, G., Mansuet‐Lupo, A., Leroy, K., & Wislez, M. (2025) · Bulletin du Cancer · doi:10.1016/s0007-4551(25)00161-4
Selvarajah, D., Kawatu, H. A., Mews, P. J., & Paver, E. C. (2025) · Interdisciplinary Neurosurgery · doi:10.1016/j.inat.2025.102028
Current and Future Applications of Liquid Biopsy in Melanoma
Feldmann, J., Pinheiro, M. A. L. L., Feldmann, J. H. L., Olivato, G. B., Awni, B. M., Lobo, M. D. M., de Menezes, J. N., Monteiro, M. R., Teixeira, F., Belfort, F. A., et al. (2025) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2025.21.1.4
Selinexor in Uveal Melanoma: A Hopeful Step or Just Another Hurdle?
de Miguel, C. A., Borea, R., & Rolfo, C. D. (2025) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-25-x2.1
Gut Microbiota and Future Research Directions
Gayen, S., Chattopadhyay, S., Hazra, R., Mallick, A., & Roy, S. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815324549125010014
Uveal Melanoma: Molecular Pathology
Coupland, S. E., Kalirai, H., Thornton, S., & Damato, B. E. (2025) · Springer eBooks · doi:10.1007/978-3-031-81354-2_10
Management of Patients with Posterior Uveal Melanoma
Damato, B. E. (2025) · Springer eBooks · doi:10.1007/978-3-031-81354-2_13
Kennedy, L. B., & Singh, A. D. (2025) · Springer eBooks · doi:10.1007/978-3-031-81354-2_28
Bechrakis, N. E. (2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65823-9_166
Reschke, R., & Hassel, J. C. (2025) · best practice onkologie · doi:10.1007/s11654-025-00653-0
Self-citationDurango, L. V., Echeverri, L. M. G., Buitrago-Bach, R., & Gómez, J. R. M. (2025) · Salud Uninorte · doi:10.14482/sun.41.02.484.070
Zanders, E. D. (2025) · Springer eBooks · doi:10.1007/978-3-031-93949-5_6 · Cited by 1
Cai, S., Xu, W., Yu, D., & Xia, Y. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1572710
Bibliometric analysis of immunotherapy in treatment of uveal melanoma
Chen, W., Zhang, H., Xiao, D., Bai, M., Luo, Y., Li, X., & Long, B. (2025) · Medicine · doi:10.1097/md.0000000000042932
Serum gp100 as an Independent Prognostic Biomarker in Early-Stage Uveal Melanoma
Bande, M. F., Piñeiro, C., Lago‐Baameiro, N., Silva, P., Pardo, M., & Blanco‐Teijeiro, M. J. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.6.80
Miller, N. J., Kwan, S. W., Leary, J. B., Hippe, D. S., McCamy, W., Veatch, J. R., Hall, E. T., Monsky, W. L., & Bhatia, S. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04124-x
Süni İntellekt əsaslı Sağqalma Təhlili əsasında Pasiyentin Yaşam Müddətinin Proqnozlaşdırılması
ETN İnformasiya Texnologiyaları İnstitutu, B., Məmmədova, M., Abdullayeva, F., & ETN İnformasiya Texnologiyaları İnstitutu, B. (2025) · Rəqəmsal tibb 4.0: problemlər, imkanlar və perspektivlər Respublika Elmi-Praktiki Konfransı · doi:10.25045/spcdh4.0.2025.42
Kayes, D., Blacklock, B., McGeachan, R. I., Scurrell, E. J., Donnelly, K., Murphy, L., Fawkes, A., Clark, R. C., Meynert, A. M., Becher, H., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-09632-5
Possibility of immunotherapy for uveal melanoma (literature review)
Тараскова, К. И., & Grishina, E. E. (2025) · POINT OF VIEW EAST – WEST · doi:10.25276/2410-1257-2025-2-58-63
Immunologische Grundlagen der Immunonkologie
Wölfel, T. (2025) · Die Onkologie · doi:10.1007/s00761-025-01791-4
Султанбаев, А. В., Тузанкина, И. А., Насретдинов, А. Ф., Султанбаева, Н. И., Меньшиков, К. В., Мусин, Ш. И., Zabelin, V. M., Ayupov, R. Т., Евгеньевич, А. В., Радимович, Р. Р., et al. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-255
Woodford, R. G., & Lim, K. H. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824465-4.00236-2
Metadata
- Authors
- Nathan, P., Hassel, J. C., Rutkowski, P., Baurain, J.-F., Butler, M. O., Schlaak, M., Sullivan, R. J., Ochsenreither, S., Dummer, R., Kirkwood, J. M., Joshua, A. M., Sacco, J. J., Shoushtari, A. N., Orloff, M., Piulats, J. M., Milhem, M., Salama, A. K. S., Curti, B., Demidov, L., Gastaud, L., Mauch, C., Yushak, M., Carvajal, R. D., Hamid, O., Abdullah, S. E., Holland, C., Goodall, H., & Piperno-Neumann, S.
- Affiliations
- University of Liverpool (GB)
- From Mount Vernon Cancer Centre, Northwood (P.N.), the Clatterbridge Cancer Centre NHS Foundation Trust, Wirral (J.J.S.), the University of Liverpool, Liverpool (J.J.S.), and Immunocore, Abingdon (S.E.A., C.H., H.G.) — all in the United Kingdom; the Department of Dermatology and the National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg (J.C.H.), the Department of Dermatology and Allergy, University Hospital, Ludwig Maximilian University of Munich, Munich (M.S.), the Department of Hematology and Oncology, Charité–Comprehensive Cancer Center (S.O.), Berlin, and the Department of Dermatology and the Center for Integrated Oncology, University Hospital Cologne, Cologne (C.M.) — all in Germany; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland (P.R.); Institut Roi Albert II des Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels (J.-F.B.); Princess Margaret Cancer Centre, Toronto (M.O.B.); Massachusetts General Hospital Cancer Ce...
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Nathan, Paul
- Hassel, Jessica C.
- Rutkowski, Piotr
- Butler, Marcus O.
- Schlaak, Max
- Sullivan, Ryan J.
- Ochsenreither, Sebastian
- Dummer, Reinhard
- Kirkwood, John M.
- Joshua, Anthony M.
- Sacco, Joseph J.
- Shoushtari, Alexander N.
- Orloff, Marlana
- Piulats, Josep M.
- Milhem, Mohammed
- Salama, April K.S.
- Curti, Brendan
- Mauch, Cornelia
- Yushak, Melinda
- Carvajal, Richard D.
- Hamid, Omid
- Abdullah, Shaad E.
- Piperno-Neumann, Sophie
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-09-23
- Volume
- 385
- Issue
- 13
- Pages
- 1196-1206
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3200574709
- Cited by
- 924
- References
- 28
- Citations by year
- 2026: 158 · 2025: 181 · 2024: 216 · 2023: 205 · 2022: 148 · 2021: 15
- FWCI
- 131.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- metastatic uveal melanoma, bispecific T-cell engagers, anti-CD3 antibody, pembrolizumab, ipilimumab, dacarbazine, overall survival, progression-free survival, HLA-A*0201, cytokine release syndrome, treatment-related adverse events, treatment-naive patients
- MeSH terms
- Ipilimumab, Cytokine Release Syndrome, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Dacarbazine, Exanthema, Female, Humans, Male, Melanoma, Middle Aged, Recombinant Fusion Proteins, Uveal Neoplasms, Survival Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
